REG - SkinBioTherapeutics - Result of AGM

SkinbiotherapeuticsAnnouncement

29/12/2023 11:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231229:nRSc2209Ya&default-theme=true

RNS Number : 2209Y  SkinBioTherapeutics PLC  29 December 2023

SkinBioTherapeutics plc

("SkinBioTherapeutics" or the "Company")

 

Results of AGM

 

29 December 2023 - SkinBioTherapeutics plc (AIM: SBTX or the
"Company") announces that at the Company's Annual General Meeting, held
today, all resolutions were duly passed.

 

Details of the proxy votes received on each resolution by the Company's
Registrar are set out below:

 

 Resolution                                                                             For & Discretionary            Against                 Withheld
                                                                                        Number of votes  %             Number of votes  %      Number of votes  %
 01      Ordinary resolution to receive and adopt the directors' and auditors' report   43,029,848       96.78%        1,413,649        3.18%  17,051           0.04%
         and the financial statements for year ended 30 June 2023
 02      Ordinary resolution for Gravita Audit Limited to be re-appointed as the        42,677,600       95.99%        448,075          1.01%  1,334,873        3.00%
         auditors of the Company until the next AGM
 03      Ordinary resolution for the Directors' to be authorised to fix the auditors'   42,958,431       96.62%        186,707          0.42%  1,315,410        2.96%
         remuneration
 04      Ordinary resolution for Stuart Ashman to be re-elected as a Director of the    39,303,678       88.40%        2,636,183        5.93%  2,520,687        5.67%
         Company
 05      Ordinary resolution for Martin Hunt to be re-elected as a Director of the      39,991,885       89.95%        2,248,346        5.06%  2,220,317        4.99%
         Company
 06      Ordinary resolution for Dr Catherine Prescott to be re-elected as a Director   40,063,946       90.11%        3,072,834        6.91%  1,323,768        2.98%
         of the Company
 07      Ordinary resolution for Danielle Bekker to be re-elected as a Director of the  42,059,615       94.60%        972,653          2.19%  1,428,280        3.21%
         Company
 08      Ordinary resolution for Manprit Singh Randhawa to be re-elected as a Director  39,716,379       89.33%        2,419,340        5.44%  2,324,829        5.23%
         of the Company
 09      Ordinary resolution to authorise the directors to allot shares                 42,030,813       94.54%        1,096,351        2.47%  1,333,384        3.00%
 10      Special resolution to authorise the directors to disapply pre-emption rights   42,285,656       95.11%        822,045          1.85%  1,352,847        3.04%
 11      Special resolution to authorise the directors to disapply pre-emption rights   42,302,981       95.15%        804,720          1.81%  1,352,847        3.04%
         in relation to an acquisition or other capital investment

 

-Ends-

 

For more information, please contact:

 SkinBioTherapeutics plc                     Tel: +44 (0) 191 495 7325
 Stuart J. Ashman, CEO

Manprit Randhawa, CFO

 Cavendish Capital Markets Limited           Tel: +44 (0) 20 7220 0500

 (Nominated Adviser & Broker)

 Giles Balleny, Dan Hodkinson

(Corporate Finance)

 Charlie Combe (Broking)

 Dale Bellis, Tamar Cranford-Smith (Sales)
 Instinctif Partners (financial press)       Tel: +44 (0) 20 7457 2020 SkinBioTherapeutics @instinctif.com
 Melanie Toyne-Sewell / Jack Kincade

 

 

Notes to Editors

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The
Company's proprietary platform technology, SkinBiotix(®), is based upon
discoveries made by Professor Catherine O'Neill and Professor Andrew McBain.

The Company is targeting a number of skin healthcare sectors, the most
advanced of which are cosmetic skincare and food supplements to modulate the
immune system by harnessing the gut-skin axis. In each area
SkinBioTherapeutics plans to exemplify its technology through human studies.
The Company's first product, AxisBiotix-Ps™, a food supplement to address
the symptoms of mild to moderate psoriasis.

The Company listed on AIM in April 2017 and is based in Newcastle, UK. For
more information, visit: www.skinbiotherapeutics.com and www.axisbiotix.com.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGNKCBQKBDDCBB